Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
															Search

		Submit


Tuberculosis (TB)


Facebook
        Twitter
        LinkedIn
        Syndicate





TB-Related Articles										Related Pages
					Return to Main Menu**2021 DTBE Publications**
Agathis NT, Bhavaraju R, Shah V, Chen L, Haley CA, Goswami ND, Patrawalla A. Challenges in LTBI care in the United States identified using a nationwide TB medical consultation databaseexternal icon. Public Health Action. 2021 Sep 21;11(3):162-166. doi: 10.5588/pha.21.0026. PMID: 34567993.
Annan E, Stockbridge EL, Katz D, Mun EY, Miller TL. A cross-sectional study of latent tuberculosis infection, insurance coverage, and usual sources of health care among non-US-born persons in the United Statesexternal icon. Medicine (Baltimore). 2021 Feb 19;100(7):e24838. doi: 10.1097/MD.0000000000024838. PMID: 33607853.Year202120202019201820172016201520142013Auld AF, Kerkhoff AD, Hanifa Y, Wood R, Charalambous S, Liu Y, Agizew T, Mathoma A, Boyd R, Date A, Shiraishi RW, Bicego G, Mathebula-Modongo U, Alexander H, Serumola C, Rankgoane-Pono G, Pono P, Finlay A, Shepherd JC, Ellerbrock TV, Grant AD, Fielding K. Derivation and external validation of a risk score for predicting HIV-associated tuberculosis to support case finding and preventive therapy scale-up: A cohort studyexternal icon. PLoS Med. 2021 Sep 7;18(9):e1003739. doi: 10.1371/journal.pmed.1003739. PMID: 34491987.
Bryant KE, Yuan Y, Engle M, Kurbatova EV, Allen-Blige C, Batra K, Brown NE, Chiu KW, Davis H, Elskamp M, Fagley M, Fedrick P, Hedges KNC, Narunsky K, Nassali J, Phan M, Phan H, Purfield AE, Ricaldi JN, Robergeau-Hunt K, Whitworth WC, Sizemore EE; AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Central monitoring in a randomized, open-label, controlled phase 3 clinical trial for a treatment-shortening regimen for pulmonary tuberculosisexternal icon. Contemp Clin Trials. 2021 Mar 10;104:106355. doi: 10.1016/j.cct.2021.106355. [Epub ahead of print]. PMID: 33713841.
Cegielski JP, Udwadia ZF, Viiklepp P, Yim JJ, Menzies D. Reply to van Deun and Decrooexternal icon. Clin Infect Dis. 2021;72:e1168-e1169. doi.org/10.1093/cid/ciaa1875.
Charles M, Richard M, Reichler MR, Koama JB, Morose W, Fitter DL. Treatment success for patients with tuberculosis receiving care in areas severely affected by Hurricane Matthew – Haiti, 2016external icon. PLoS One. 2021 Mar 17;16(3):e0247750. doi: 10.1371/journal.pone.0247750. PMID: 33730043.
Chorba T. Strange Case of a Sojourn in Saranacexternal icon. Emerg Infect Dis. 2021 Mar;27(3):994–5. doi: 10.3201/eid2703.AC2703. PMCID: PMC7920687.
Collins JM, Stout JE, Ayers T, Hill AN, Katz DJ, Ho CS, Blumberg HM, Winglee K; Tuberculosis Epidemiologic Studies Consortium. Prevalence of Latent Tuberculosis Infection Among Non-US-Born Persons by Country of Birth-United States, 2012-2017external icon. Clin Infect Dis. 2021 Nov 2;73(9):e3468-e3475. doi: 10.1093/cid/ciaa1662. PMID: 33137172.
Deutsch-Feldman M, Pratt RH, Price SF, Tsang CA, Self JL. Tuberculosis — United States, 2020. MMWR Morb Mortal Wkly Rep. 2021 Mar 26; 70(12):409–414. doi: 10.15585/mmwr.mm7012a1.
Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH, Pierre S, Purfield AE, Samaneka W, Savic RM, Sanne I, Scott NA, Shenje J, Sizemore E, Vernon A, Waja Z, Weiner M, Swindells S, Chaisson RE; AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosisexternal icon. N Engl J Med. 2021 May 6;384(18):1705-1718. doi: 10.1056/NEJMoa2033400. PMID: 33951360.
Feng PJ, Wu Y, Ho CS, Chinna L, Whelen AC, Largen A, Brostrom R, Reves R, Belknap R, Cattamanchi A, Banaei N. Impact of T-Cell Xtend on T-SPOT. TB Assay in High-Risk Individuals after Delayed Blood Sample Processingexternal icon. J Clin Microbiol. 2021 Mar 3:JCM.00120-21. doi: 10.1128/JCM.00120-21. [Epub ahead of print]. PMID: 33658266.
Gewitz AD, Solans BP, Mac Kenzie WR, Heilig C, Whitworth WC, Johnson JL, Nsubuga P, Dorman S, Weiner M, Savic RM; Tuberculosis Trials Consortium of the Centers for Disease Control Prevention. A Longitudinal Model-Based Biomarker Analysis of Exposure Response in Adults with Pulmonary Tuberculosisexternal icon. Antimicrob Agents Chemother. 2021 Jul 12:AAC0179420. doi: 10.1128/AAC.01794-20. [Epub ahead of print]. PMID: 34252302.
Ghosh S, Felix D, Kammerer JS, Talarico S, Brostrom R, Starks A, Silk B. Evaluation of Sputum-Culture Results for Tuberculosis Patients in the United States-Affiliated Pacific Islandsexternal icon. Asia Pac J Public Health. 2021 Dec 7:10105395211060119. doi: 10.1177/10105395211060119. [Epub ahead of print]. PMID: 34872367.
Harrist AV, McDaniel CJ, Wortham JM, Althomsons SP. Developing National Genotype-Independent Indicators for Recent Mycobacterium Tuberculosis Transmission Using Pediatric Cases-United States, 2011-2017external icon. Public Health Rep. 2021 Feb 19:33354920985215. doi: 10.1177/0033354920985215. [Epub ahead of print]. PMID: 33606947.
Ho CS, Feng PI, Narita M, Stout JE, Chen M, Pascopella L, Garfein R, Reves R, Katz DJ; Tuberculosis Epidemiologic Studies Consortium. Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort studyexternal icon. Lancet Infect Dis. 2021 Sep 6:S1473-3099(21)00145-6. doi: 10.1016/S1473-3099(21)00145-6. [Epub ahead of print]. PMID: 34499863.
Iqbal SA, Isenhour CJ, Mazurek G, Langer AJ, Chang MH, Truman BI. Factors Associated With Latent Tuberculosis Infection Treatment Failure Among Patients With Commercial Health Insurance-United States, 2005-2016external icon. J Public Health Manag Pract. 2021 Jul-Aug 01;27(4):E151-E161. doi: 10.1097/PHH.0000000000001077. PMID: 31688742.
Kaniga K, Hasan R, Jou R, Vasiliauskienė E, Chuchottaworn C, Ismail N, Metchock B, Miliauskas S, Viet Nhung N, Rodrigues C, Shin S, Simsek H, Smithtikarn S, Ngoc ALT, Boonyasopun J, Kazi M, Kim S, Kamolwat P, Musteikiene G, Sacopon CA, Tahseen S, Vasiliauskaitė L, Wu MH, Vally Omar S. Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective In Vitro Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolatesexternal icon. J Clin Microbiol. 2022 Jan 19;60(1):e0291920. doi: 10.1128/JCM.02919-20. Epub 2021 Oct 27. PMID: 34705538.
Katrak SS, Li R, Reynolds S, Marks SM, Probst JR, Chorba T, Winthrop K, Castro KG, Goswami ND. Association of Tumor Necrosis Factor α Inhibitor Use with Diagnostic Features and Mortality of Tuberculosis in the United States, 2010–2017external icon. Open Forum Infect Dis. 2021 Dec 22;9(2):ofab641. doi: 10.1093/ofid/ofab641. Epub 2021 Dec 22. PMID: 35106318.
Kim S, Cohen T, Horsburgh CR, Miller JW, Hill AN, Marks SM, Li R, Kammerer JS, Salomon JA, Menzies NA. Trends, mechanisms, and racial/ethnic differences of tuberculosis incidence in the US-born population aged 50 years or older in the United Statesexternal icon. Clin Infect Dis. 2021 Jul 29:ciab668. doi: 10.1093/cid/ciab668. [Epub ahead of print]. PMID: 34323959.
Kumar V, Dalton TL, Armstrong LR, Whitesell A, Li R, Starks AM, Use of Nucleic Acid Amplification Testing for Rapid Detection of Mycobacterium tuberculosis Complex Among US Tuberculosis Patients, 2011‒2017. Open Forum Infect Dis. 2021 Nov; 8(11): ofab528. https://doi.org/10.1093/ofid/ofab528external icon.
Labuda SM, McDaniel C, Talwar A, Braumuller A, Parker S, McGaha S, Blissett C, Wortham J, Mukasa L, Stewart RJ. Tuberculosis Outbreak Associated With Delayed Diagnosis and Long Infectious Periods in Rural Arkansas, 2010-2018external icon. Public Health Rep. 2021 Mar 17:33354921999167. doi: 10.1177/0033354921999167. [Epub ahead of print]. PMID: 33729050.
Largen A, Ayala A, Khurana R, Katz DJ, Venkatappa TK, Brostrom R. Evaluation of point-of-care algorithms to detect diabetes during screening for latent TB infectionexternal icon. Int J Tuberc Lung Dis. 2021 Jul 1;25(7):547-553. doi: 10.5588/ijtld.21.0013. PMID: 34183099.
Li R, Wilson WW, Schwartz NG, Hernandez-Romieu AC, Glowicz J, Hanlin E, Taylor M, Pelkey H, Briody CA, Gireesh L; DNP5, Eskander M, Lingenfelter K, Althomsons SP, Stewart RJ, Free R, Annambhotla P, Basavaraju SV, Wortham JM, Morris SB, Benowitz I, Haddad MB, Hong R, Drees M. *Notes from the Field*: Tuberculosis Outbreak Linked to a Contaminated Bone Graft Product Used in Spinal Surgery — Delaware, March–June 2021external icon. MMWR Morb Mortal Wkly Rep. 2021 Sep 10;70(36):1261-1263. doi: 10.15585/mmwr.mm7036a4. PMID: 34499629.
Liu Y, Posey DL, Yang Q, Weinberg MS, Maloney SA, Lambert LA, Ortega LS, Marano N, Cetron MS, Phares CR. Multidrug-resistant Tuberculosis in U.S.-bound Immigrants and Refugeesexternal icon. Ann Am Thorac Soc. 2021 Dec 23. doi: 10.1513/AnnalsATS.202105-580OC. [Epub ahead of print]. PMID: 34941475.
Mancuso JD, Miramontes R, Winston CA, Horsburgh CR Jr, Hill AN. Self-Reported Engagement in Care among U.S. Residents with Latent Tuberculosis Infection – 2011-2012external icon. Ann Am Thorac Soc. 2021 Oct;18(10):1669-1676. doi: 10.1513/AnnalsATS.202009-1153OC. PMID: 33684324. PMCID: PMC8423850.
Menzies NA, Shrestha S, Parriott A, Marks SM, Hill AN, Dowdy DW, Shete PB, Cohen T, Salomon JA. The health and economic benefits of tests that predict future progression to tuberculosis diseaseexternal icon. Epidemiology. 2021 Sep 9. doi: 10.1097/EDE.0000000000001418. [Epub ahead of print]. PMID: 34669631.
Mirzazadeh A, Kahn JG, Haddad MB, Hill AN, Marks SM, Readhead A, Barry PM, Flood J, Mermin JH, Shete PB. State-level prevalence estimates of latent tuberculosis infection in the United States by medical risk factors, demographic characteristics and nativityexternal icon. PloS One. 2021 Apr 1;16(4):e0249012. doi: 10.1371/journal.pone.0249012. eCollection 2021. PMID: 33793612.
Nabity SA, Han E, Lowenthal P, Henry H, Okoye N, Chakrabarty M, Chitnis AS, Kadakia A, Villarino E, Low J, Higashi J, Barry PM, Jain S, Flood J. Sociodemographic Characteristics, Comorbidities, and Mortality Among Persons Diagnosed With Tuberculosis and COVID-19 in Close Succession in California, 2020external icon. JAMA Netw Open. 2021 Dec 1;4(12):e2136853. doi: 10.1001/jamanetworkopen.2021.36853. PMID: 34860244.
Narita M, Hatt G, Toren KG, Vuong K, Pecha M, Jereb JA, Goswami Delayed Tuberculosis Diagnoses During the COVID-19 Pandemic in 2020 — King County, Washingtonexternal icon. Clin Infect Dis. 2021 May 6:ciab387. doi: 10.1093/cid/ciab387. [Epub ahead of print]. PMID: 33956137.
Nelson KN, Talarico S, Poonja S, McDaniel CJ, Cilnis M, Chang AH, Raz K, Noboa WS, Cowan L, Shaw T, Posey J, Silk BJ. Mutation of *Mycobacterium tuberculosis* and Implications for Using Whole-Genome Sequencing for Investigating Recent Tuberculosis Transmissionexternal icon. Front Public Health. 2022 Jan 13;9:790544. doi: 10.3389/fpubh.2021.790544. eCollection 2021. PMID: 35096744. PMCID: PMC8793027.
Njie GJ, Khan A. Prevalence of Tuberculosis and Mental Disorders Comorbidity: A Systematic Review and Meta-analysisexternal icon. J Immigr Minor Health. 2021 Nov 18. doi: 10.1007/s10903-021-01312-6. [Epub ahead of print]. PMID: 34796457.
Parmer J, Macario E, Tatum K, Brackett A, Allen L, Picard R, DeLuca N, Dowling M. Latent tuberculosis infection: Misperceptions among non-U.S.-born-populations from countries where tuberculosis is commonexternal icon. Glob Public Health. 2021 Jul 6:1-15. doi: 10.1080/17441692.2021.1947342. [Epub ahead of print]. PMID: 34228584.
Pettit AC, Stout JE, Belknap R, Benson CA, Séraphin MN, Lauzardo M, Horne DJ, Garfein RS, Maruri F, Ho CS; Tuberculosis Epidemiologic Studies Consortium (TBESC). Optimal Testing Choice and Diagnostic Strategies for Latent Tuberculosis Infection Among US-Born People Living with Human Immunodeficiency Virus (HIV)external icon. Clin Infect Dis. 2021 Oct 5;73(7):e2278-e2284. doi: 10.1093/cid/ciaa1135. PMID: 32761083.
Podany AT, Pham M, Sizemore E, Martinson N, Samaneka W, Mohapi L, Badal-Faesen S, Dawson R, Johnson JL, Mayanja H, Lalloo U, Whitworth WC, Pettit A, Campbell K, Phillips P, Bryant K, Scott N, Vernon A, Kurbatova E, Chaisson RE, Dorman S, Nahid P, Swindells S, Dooley KE, Fletcher CV; AIDS Clinical Trials Group & Tuberculosis Trials Consortium. Efavirenz pharmacokinetics and HIV-1 viral suppression among patients receiving TB treatment containing daily high-dose rifapentineexternal icon. Clin Infect Dis. 2021 Dec 16:ciab1037. doi: 10.1093/cid/ciab1037. [Epub ahead of print]. PMID: 34918028.
Radtke KK, Ernest JP, Zhang N, Ammerman NC, Nuermberger E, Belknap R, Boyd R, Sterling TR, Savic RM. Comparative efficacy of rifapentine alone and in combination with isoniazid for latent tuberculosis infection: a translational pharmacokinetic-pharmacodynamic modelling studyexternal icon. Antimicrob Agents Chemother. 2021 Oct 4:AAC0170521. doi: 10.1128/AAC.01705-21. [Epub ahead of print]. PMID: 34606336.
Rodriguez CA, Li T, Self JL, Jenkins HE, Horsburgh CR, White LF. Genotyping indicates marked heterogeneity of tuberculosis transmission in the United States, 2009–2018external icon. Epidemiol Infect. 2021 Sep 14;149:e215. doi: 10.1017/S0950268821002041.
Scott NA, Lee KK, Sadowski C, Kurbatova EV, Goldberg SV, Nsubuga P, Kitshoff R, Whitelaw C, Thuy HN, Batra K, Allen-Blige C, Davis H, Kim J, Phan M, Fedrick P, Chiu KW, Heilig CM, Sizemore E; AIDS Clinical Trials Group and The Tuberculosis Trials Consortium. Optimizing drug inventory management with a web-based information system: The TBTC Study 31/ACTG A5349 experienceexternal icon. Contemp Clin Trials. 2021 Jun;105:106377. doi: 10.1016/j.cct.2021.106377. Epub 2021 Mar 29. PMID: 33794353.
Self JL, McDaniel CJ, Bamrah Morris S, Silk BJ. Estimating and Evaluating Tuberculosis Incidence Rates Among People Experiencing Homelessness, United States, 2007-2016external icon. Med Care. 2021 Apr 1;59(Suppl 2):S175-S181. doi: 10.1097/MLR.0000000000001466. PMID: 33710092.
Smith JP, Gandhi NR, Silk BJ, Cohen T, Lopman B, Raz K, Winglee K, Kammerer S, Benkeser D, Kramer M, Hill AN. A cluster-based method to quantify individual heterogeneity in tuberculosis transmissionexternal icon. Epidemiology. 2021 Dec 8. doi: 10.1097/EDE.0000000000001452. Epub ahead of print. PMID: 34907974.
Springer YP, Kammerer JS, Silk BJ, Langer AJ. Tuberculosis in Indigenous Persons – United States, 2009-2019external icon. J Racial Ethn Health Disparities. 2021 Aug 26. doi: 10.1007/s40615-021-01112-6. [Epub ahead of print]. PMID: 34448124.
Talwar A, Li R, Langer AJ. Association between Birth Region and Time to Tuberculosis Diagnosis among Non–US-Born Persons in the United Statesexternal icon. Emerg Infect Dis. 2021 Jun;27(6):1645-1653. doi: 10.3201/eid2706.203663. PMID: 34013876.
Winglee K, McDaniel CJ, Linde L, Kammerer S, Cilnis M, Raz KM, Noboa W, Knorr J, Cowan L, Reynolds S, Posey J, Sullivan Meissner J, Poonja S, Shaw T, Talarico S, Silk BJ. Logically Inferred Tuberculosis Transmission (LITT): A Data Integration Algorithm to Rank Potential Source Casesexternal icon. Front Public Health. 2021 Jun 21;9:667337. doi: 10.3389/fpubh.2021.667337. eCollection 2021. PMID: 34235130.
Wortham JM, Li R, Althomsons SP, Kammerer S, Haddad MB, Powell KM. Tuberculosis Genotype Clusters and Transmission in the U.S., 2009-2018external icon. Am J Prev Med. 2021 May 12:S0749-3797(21)00165-3. doi: 10.1016/j.amepre.2021.02.006. [Epub ahead of print]. PMID: 33992497.
Zetola NM, Moonan PK, Click E, Oeltmann JE, Basotli J, Wen XJ, Boyd R, Tobias JL, Finlay A, Modongo C. Population-Based Geospatial and Molecular Epidemiologic Study of Tuberculosis Transmission Dynamics, Botswana, 2012-2016external icon. Emerg Infect Dis. 2021 Mar;27(3):835-844. doi: 10.3201/eid2703.203840. PMID: 33622470.
Zhang N, Savic RM, Boeree MJ, Peloquin C, Weiner M, Heinrich N, Bliven-Sizemore E, Phillips PP, Hoelscher M, Whitworth W, Morlock G, Posey J, Stout JE, Mac Kenzie W, Aarnoutse R, Dooley KE; Tuberculosis Trials Consortium (TBTC) and Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA) Networks. Optimising pyrazinamide for the treatment of tuberculosisexternal icon. Eur Respir J. 2021 Feb 4:2002013. doi: 10.1183/13993003.02013-2020. [Epub ahead of print]. PMID: 33542052.
							
					
						Page last reviewed:  February 9, 2022					Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue